July 2024

 

Clinical trial participants are essential in the quest for new treatments and a cure for PF.

Each month in this newsletter, we'll highlight just a few of the many trials that are open for enrollment and seeking volunteers.


To view more available trials for various forms of interstitial lung disease, please visit the PFF Clinical Trial Finder.

 

Featured trials of the month

 

Seeking participants with:

idiopathic pulmonary fibrosis


Oral Ifetroban in Patients With IPF

Study ID: NCT05571059

Trial Phase: Phase 2

Intervention: Oral drug

Sponsor: Cumberland Pharmaceuticals

Study Contact: Ines Macias-Perez, PhD (615.979.5778, imaciasperez@cumberlandpharma.com); Ingrid Anderson, PhD, CCRP (615.627.4121, ianderson@cumberlandpharma.com)

Learn more about this study
Learn more about this drug

Seeking participants with:

idiopathic pulmonary fibrosis


Study of TTI-101 in Participants With IPF

Study ID: NCT05671835

Trial Phase: Phase 2

Intervention: Oral drug

Sponsor: Tvardi Therapeutics, Incorporated

Study Contact: info@tvardi.com

Learn more about this study
Learn more about this drug

Seeking participants with:

myositis associated interstitial lung disease


MINT

Study ID: NCT05799755

Trial Phase: Phase 4

Intervention: Oral drug

Sponsor: University of Pittsburgh

Study Contact: Solciris Dominguez (646.600.4204, sad408@pitt.edu)

Learn more about this study
Learn more about this drug
 

Study spotlight

Advocate for access to supplemental oxygen by sharing your or your loved one’s experience using oxygen


Many patients are unable to receive the oxygen equipment, supplies, and services that they need to maintain their health. The Pulmonary Fibrosis Foundation is currently advocating in favor of the Supplemental Oxygen Access Reform (SOAR) Act, which was introduced in the U.S. Congress in early 2024. The SOAR Act will improve Medicare patients’ ability to access the necessary and appropriate oxygen equipment, supplies, and services. Learn more about the Four Pillars for Supplemental Oxygen Reform that provide the basis of the SOAR Act.


We are asking patients who use oxygen, patients who have used oxygen in the past, as well as their caregivers, family members, and healthcare providers, to share their stories of using supplemental oxygen by completing this form. We may use some of these stories to highlight the need for reform to how Medicare patients receive supplemental oxygen. Stories may be shared on social media, with government officials, or through other channels to demonstrate the benefits that the SOAR Act would have for the community. Share your oxygen story today!



If you have any questions or comments about this newsletter, please contact partnerships@pulmonaryfibrosis.org. 

Quick Links



...About PF ... Breathe Bulletin ... Annual Report ... Contact us


Facebook  Twitter  Instagram  Linkedin  Youtube  
Disclaimer: The PFF does not promote or represent that any investigational new drugs mentioned are safe or effective. The information provided is for general information only and is not intended as medical or other professional advice. It should not be relied upon as a substitution for consultation with qualified professionals who are familiar with your individual needs. The PFF does not recommend any commercial product or services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

About the Pulmonary Fibrosis Foundation 

The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers. For more information, visit pulmonaryfibrosis.org or call 844.TalkPFF (844.825.5733) or +1 312.587.9272 from outside of the US. 


The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program® and has earned the Guidestar Platinum Seal of Transparency For more information, please visit our website.